Sanofi started 2022 on a good note, with solid growth being witnessed across the divisions. In Q1, Dupixent continued its good run, and was well-complemented by a recovering Consumer Healthcare business. While the individual Vaccines performance was slightly mixed, it remains well-poised to capitalize on recovering demand post the COVID-19 disruption. Overall, the firm’s transformation journey remains on track and, hence, our positive stock recommendation is maintained.

28 Apr 2022
Q1 - a good start to the year

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 - a good start to the year
- Published:
28 Apr 2022 -
Author:
Amandeep Goyal -
Pages:
5 -
Sanofi started 2022 on a good note, with solid growth being witnessed across the divisions. In Q1, Dupixent continued its good run, and was well-complemented by a recovering Consumer Healthcare business. While the individual Vaccines performance was slightly mixed, it remains well-poised to capitalize on recovering demand post the COVID-19 disruption. Overall, the firm’s transformation journey remains on track and, hence, our positive stock recommendation is maintained.